Audience:
Reproductive healthcare professionals FDA and Wyeth revised the prescribing information
to include a boxed warning, which states that estrogens and estrogens plus progestin
therapies should not be used for the prevention of cardiovascular disease.
The
boxed warning includes risk information from the Women's Health Initiative (WHI)
study. The study reported increased risks of myocardial infarction, stroke, invasive
breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women
during 5 years of treatment with conjugated equine estrogens (0.625 mg) combined
with medroxyprogesterone acetate (2.5 mg) relative to placebo. Because of these
risks, estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.
*Many cases are in
the investigative stages, but make a complaint now and your case can be evaluated.
Find out if you are owed money for damages and injury?